

AT A GLANCE

NASDAQ: GILD
 Founded: 1987
 HQ: Foster City, CA

\$90.62B
 Market Cap
 (as of 2/4/2019)



~**11,000**
 Employees



Presence in
>35 Countries
 across
6 Continents



4 Primary Therapeutic
 Areas of Focus:

- HIV
- Liver Disease
- Oncology
- Inflammation

4Q18 FINANCIALS

PRODUCT REVENUE

\$5.7B

NON-GAAP EPS


\$1.44

OPERATING CASH FLOW


\$2.3B

SELECTED PIPELINE PRODUCT CANDIDATES


HIV




Liver Diseases



Hematology / Oncology



Inflammation / Respiratory



COMMERCIAL PORTFOLIO HIGHLIGHTS

Human Immunodeficiency Virus (HIV)

Treatment:



Prevention:



Hepatitis C Virus (HCV)



Hepatitis B Virus (HBV)



Hematology / Oncology



ANALYST COVERAGE

Argus, Atlantic Equities, Baird, BofA Merrill Lynch, Barclays, Cantor Fitzgerald, Citi, Cowen & Company, Evercore ISI, Goldman Sachs, Guggenheim Securities, Jefferies, JPMorgan, Maxim Group, Mizuho, Moody's, Morgan Stanley, Morningstar, Needham, Oppenheimer, Piper Jaffray, Raymond James, RBC, Standard and Poors, SVB Leerink, UBS, Wells Fargo, William Blair